Andrew Cheng, President en CEO van Akero Therapeutics, Inc. (NASDAQ:AKRO), een biotechnologiebedrijf dat volgens InvestingPro -analyse momenteel tekenen van onderwaardering vertoont, heeft op 11 augus ...

Jonathan Young, Chief Operating Officer van Akero Therapeutics, Inc. (NASDAQ:AKRO), heeft op 12 augustus 2025 in meerdere transacties 12.500 gewone aandelen verkocht. De verkopen werden uitgevoerd teg ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics Inc. (NASDAQ:AKRO) Akero Therapeutics soared by 97.52 percent in Monday’s trading to close at $51.71 per share following promising treatment results on liver disease.

Akero Therapeutics has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic ...

Akero Therapeutics has a twelve month low of $17.86 and a twelve month high of $58.40. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of -13.19 and a beta of -0.11.

Akero Therapeutics, Inc. has successfully completed its underwritten public offering, selling 6,427,170 shares of common stock at $48.00 per share, including an over-allotment option for an ...